Indaptus Therapeutics, Inc. reported on February 26, 2026, that shareholders approved several significant measures, including the issuance of 111 million common shares upon conversion of preferred stocks and the ability for the board to perform reverse stock splits ranging from 1-for-2 to 1-for-199. The stockholders also increased the number of authorized shares to 1 billion and elected new board members, strengthening management control.